An Open-Label Study to Assess the Effect of CYP2D6 Inhibitor Paroxetine on the Single-Dose Pharmacokinetics of JNJ-31001074 in Healthy Subjects.
Phase of Trial: Phase I
Latest Information Update: 04 Jun 2014
At a glance
- Drugs Bavisant (Primary) ; Paroxetine
- Indications Attention-deficit hyperactivity disorder; Depression; Generalised anxiety disorder; Obsessive-compulsive disorders; Panic disorder; Post-traumatic stress disorders; Premenstrual dysphoric disorder; Social phobia
- Focus Pharmacogenomic; Pharmacokinetics
- Sponsors Janssen Research & Development
- 19 Mar 2012 Actual initiation date changed from Sep 2010 to Aug 2010 as reported by ClinicalTrials.gov.
- 04 Nov 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 16 Sep 2010 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.